RESUMEN
There are no published data on Australian adult cystic fibrosis (CF) patient outcomes post bronchial arterial embolisation (BAE). We report 20 years of experience of BAE at a major Australian tertiary adult CF centre, where 46 patients underwent 100 BAE during this period. Mortality rate was comparable to previous studies (4% per year) and most who died had repeat BAE requirements. A higher proportion (9 out of 45) of patients were transplanted compared to previous publications. Repeat BAE was common and significantly higher in patients already on tranexamic acid.
Asunto(s)
Fibrosis Quística , Hemoptisis , Adulto , Australia/epidemiología , Arterias Bronquiales/diagnóstico por imagen , Fibrosis Quística/complicaciones , Fibrosis Quística/terapia , Hemoptisis/etiología , Hemoptisis/terapia , Humanos , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
The aim of this study was to evaluate the incidence of long-term oxygen therapy (LTOT)-related adverse outcomes in our health service. LTOT patients retrospectively recruited had their medical records reviewed for the period of 1 January 2014 to 30 June 2018. Burns, physical injuries, any falls attributable to LTOT requiring admission were the outcomes measured. Of 291 patients, four patients required admission due to LTOT-related adverse events where three admissions were related to falls secondary to tripping over oxygen tubing.
Asunto(s)
Quemaduras/epidemiología , Hipoxia/terapia , Terapia por Inhalación de Oxígeno/efectos adversos , Enfermedad Pulmonar Obstructiva Crónica/terapia , Accidentes por Caídas/estadística & datos numéricos , Anciano , Australia/epidemiología , Quemaduras/etiología , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Hipoxia/fisiopatología , Incidencia , Masculino , Terapia por Inhalación de Oxígeno/métodos , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Estudios Retrospectivos , Factores de Riesgo , Fumar/epidemiologíaRESUMEN
Despite proven effectiveness in treating tachyarrhythmias, sotalol is proarrhythmic and can cause torsades de pointes. Given the emergence of studies that show no benefit from rhythm control strategies in managing atrial fibrillation, as well as the introduction of nonpharmacological approaches to treating arrhythmias, we felt it necessary to ascertain if there was any role for sotalol given its side effects. Review of the literature regarding sotalol use in the prevention and treatment of supraventricular and ventricular tachyarrhythmias seems to show that more effective and safer agents and nonpharmacological alternatives are currently available. However, sotalol still seems to be useful in preventing supraventricular tachyarrhythmias postcardiac surgery and in reverting hemodynamically stable sustained ventricular tachycardias in the setting of coronary artery disease. Its role in the prevention of tachyarrhythmias in the setting of arrhythmogenic right ventricular cardiomyopathy requires further investigation.